Cleaning Verification: Method Development and Validation Using Ion Mobility Spectrometry

Pharmaceutical Technology, Pharmaceutical Technology-07-02-2009, Volume 33, Issue 7

The authors discuss the theory of ion mobility spectrometry, its benefit over HPLC analysis in cleaning verification, and the experimental considerations for method validation and validation.

The cleanliness of manufacturing and packaging equipment in the pharmaceutical industry is critical to ensure product efficacy, personal safety, and the absence of unwanted active pharmaceutical ingredient (API) before the introduction of a different compound. Upon completion of processing a drug substance or tablet formulation, a detergent cleans each part of the pharmaceutical equipment.

(AARON GRAUBART, PAUL TEARLE/GETTY IMAGES)

The cleaning verification process in the pharmaceutical industry involves several steps. First, the clinical supply or manufacturing unit of a company submits samples for analysis following the equipment cleaning process. The sample analysis is completed by an analytical department or quality control (QC) personnel. The results are reported back to the clinical supply unit, and the process is repeated until all samples have met the acceptable residual limit (ARL). The subject exposure limit (SEL) (in units of mg/subject/day) for a given compound is provided by a drug-safety evaluation group and is an industry-wide practice. The ARL of the API in each swab sample is a set at one-tenth of the SEL.

These types of samples have been analyzed by high-performance liquid chromatography (HPLC). In an effort to significantly reduce sample turnaround time, which can take as long as several days, ion mobility spectrometry (IMS) has been evaluated as an alternative method for analysis (1–4). The time taken for analysis is important because the faster that cleaning can be confirmed, the faster the plant can return to operation. This article discusses the theory of IMS, the benefit of IMS over HPLC analysis, and experimental considerations for method development and validation.

Theory

IMS is a type of separation technique, similar to time-of-flight mass spectrometry, that distinguishes ions of a given compound based on their velocities through a drift tube under the influence of a weak electric field. The technique characterizes chemical substances based on their gas-phase ion mobilities and provides detection and quantitation of trace analytes (1). There are several IMS instrument vendors. Figure 1 shows the IonScan-LS ion mobility spectrometer with the Cobra autosampler (Smiths Detection, Warren, NJ), which was used in the studies described in this article.

Figure 1: The IonScan-LS ion mobility spectometer with the Cobra autosampler.(FIGURES COURTESY OF THE AUTHORS)

To perform the IMS analysis, a sample solution containing a compound of interest is injected by the autosampler onto a PTFE substrate and allowed to dry. Figure 2 shows the sample inlet, ionization chamber, drift tube, and detector (5). Sample is introduced by heating the substrate to ~290 °C, which results in desorption or vaporization of the sample into an inlet tube. Primary ion formation occurs through atmospheric pressure chemical ionization (APCI) using nickel-63 as the radioactive source. Following many collisions, product ions are formed and gated into the drift tube. These ions-based on size, shape, and charge-travel through the drift tube toward the detector at different velocities. In contrast to mass spectrometers, separation of ions is based on a size–charge relationship rather than the mass–charge ratio (6).

Figure 2: Cross-sectional view of the ion mobility spectrometer sample inlet, ionization chamber, drift tube, and detector.

IMS distinguishes ions of a given compound on the basis of their velocities through a drift tube under the influence of a weak electric field. Ion velocity (v) is proportional to the applied electric field (E)

in which K is the ion mobility in units of cm2 /Vs. Drift time t is proportional to 1/K , ion mass m, and collisional cross section C.

Reduced mobility Ko for an analyte is calculated by normalizing its drift time to that of the internal calibrant as in the following equation:

in which (KoC ) is the reduced mobility of the calibrant and t C is the drift time of the calibrant.

These velocities, or ion mobilities, are determined and selective for a given compound. The high sensitivity of the instrument (nanogram to picogram range) provides for an excellent technique to quickly verify equipment cleanliness. Figure 3 illustrates the separation process described in the theory above. This technique allows for positive or negative mode of detection. Each mode has a unique internal calibrant used for calculation of the Ko. In the positive mode the internal calibrant is nicotinamide. In the negative mode the internal calibrant is methyl salicylate.

Figure 3: Illustration of ions of varying sizes migrating toward the detector through a constant flow of air.

Advantages of IMS

Ion mobility has unique advantages over the conventional HPLC technique for cleaning verification. Although the principles of IMS technology have been well established, its uses in the pharmaceutical industry have, until recently, been limited. This has been changed by the development of easy-to-use commercial instruments of moderate cost, with small footprint and high sensitivity (4). As shown in Figure 4, when compared with the typical HPLC method, the IMS technique can save a significant amount of time in the analyzing cleaning verification samples. Furthermore, a quick response time in getting results can reduce down time of key manufacturing and packaging equipment, ultimately leading to significant cost savings and increased productivity for the company (1,3).

Figure 4: Efficiency gained by ion mobility spectrometry (IMS) versus high-performance liquid chromatography (HPLC).

Method development

As with most analytical methods, the IMS instrument parameters must be examined and optimized for each compound as part of method development. These parameters include ionization mode, desorber temperature, injection volume, post-injection delay, drift flow velocity, and analysis time. The development process begins by examining the selectivity of the target compound in both positive and negative modes. In the authors' experience, most pharmaceutical compounds respond better in the positive mode because of the presence of basic functional groups within the molecule. The desorber temperature for compounds analyzed in the positive mode is typically set at ~290 °C. This temperature should be hot enough to effectively desorb the sample off the substrate but not so hot as to thermally degrade the compound. Typical sample volumes are 1 µL, injected using a 10-µL syringe. The post-injection delay is dependent on this volume and the type of solvent being used. A large injection volume of a solvent of low volatility requires a longer post-injection delay because it will take more time for the solvent to evaporate. Finally, the analysis time and drift flow velocity settings are dependent on the IMS response. A sufficient analysis time and drift flow are necessary to ensure depletion of all sample ions in the drift tube. In a case where the analysis time is too short, or drift flow velocity is too low, sample carryover may be an issue.

The generally accepted practice is that an analytical method must exhibit sufficient sensitivity to measure the concentration at the ARL of the active agent or degradants being investigated in the swab and rinse samples. Typically, a limit test is used to establish a pass–fail criterion for swab samples and determine whether the manufacturing equipment is clean. Determining the pass–fail limit is accomplished by evaluating the instrument response curve and the system's precision. It allows analysts to capture the ARL within a linear calibration range, therefore providing an accurate means of determining the cleanliness of equipment parts. In the response curve, the "target level" represents the highest point within linear range (see Figure 5). The "action level" represents the resulting pass–fail level after adjusting the target level for instrument response variability.

Figure 5: Second-order polynomial calibration curve.

Any sample that responds above this action level registers as a failure. Any sample that responds below this action level registers as passing. Consequently, there is an area of uncertainty between the target and action level within which false-positive results may occur. However, these are generally infrequent occurrences.

Method validation

Typical IMS method validation parameters to be considered include selectivity, linearity, reproducibility, recovery and solution stability. Selectivity of the analyte is determined based on evaluation of the molecular structure dictating the mode of detection. Selectivity from the sample matrix is based on minimizing the interference from product excipients and cleaning detergents, and should be examined before performing the recovery experiment. In addition, the linearity is based on a second-order polynomial curve obtained from the response versus the amount introduced, as described previously. Reproducibility must be used to determine the action level. Therefore, these parameters must be considered during method development and verified during validation.

Recovery. After determination of the action level, sample recovery is determined from a 10-in.2 stainless-steel coupon. A stock sample solution is prepared at 100% of the API concentration at the target level. The solution is then spiked onto three separate stainless steel coupons. The surfaces are allowed to dry before swabbing with a clean Texwipe alpha polyester swab. According to industry guidelines, the swabbing technique includes horizontal strokes to swab the entire designated area with one side of the swab head and then vertical strokes with the other side of the swab head. Each swab is then placed back into the vial containing sample diluent, extracted, and later analyzed for active content. Table I shows the recovery values from stainless-steel surfaces and corresponding percent relative standard deviation (%RSD) at the action level for a novel pharmaceutical compound under development.

Table I: Recovery of active from factory-finished, stainless-steel plates.

Table I shows the recovery results, which are typical of those generated by swabbing three different stainless-steel coupons. The observed variation is primarily a result of the inherent variability in the surface finish of the coupon. These values are independent of the analysis technique and may be optimized by adjusting the swabbing procedure and/or materials. However, application of a predetermined correction factor to swab assay results can be used to compensate for recovery values as low as 50% during method validation.

Solution stability. Sample and standard solution stability studies are typically performed to cover 24 h at room temperature. Additional validation studies, such as robustness and intermediate precision, are not included in the authors' validation plan for a limit test. All of the parameters described previously must meet pre-established criteria as defined in the validation protocol. The criteria and validation protocol must conform to International Conference on Harmonization guidelines as well as internal standard operating procedures.

Conclusion

The ease of use and the small footprint of ion mobility spectrometry instrument allows for the system to be implemented in various work environments, such as quality control, and to report results with great sensitivity (nanogram to picogram range). Moreover, data reduction software package upgrade ensures 21 CFR Part 11 compliance. The use of this software, in addition to a limit test, has simplified the process of data manipulation, resulting in high-confidence passes for each clean sample analyzed.

Elizabeth Galella* is a research scientist, Scott Jennings is a senior research scientist, Madhavi Srikoti is an associate research scientist, Elizabeth Bonasso is a research scientist, all at the analytical research and development unit of the Pharmaceutical Research Institute, Bristol-Myers Squibb, One Squibb Drive, New Brunswick, NJ 08903, elizabeth.galella@bms.com.

*To whom all correspondence should be addressed.Submitted: Oct. 20, 2008. Accepted: Dec. 30, 2008.

What would you do differently? Submit your comments about this paper in the space below.

References

1. G. Walia et al., "Using Ion Mobility Spectrometry for Cleaning Verification in Pharmaceutical Manufacturing," Pharm. Technol. 27 (4), 72–78 (2002).

2. G. Walia et al., "Implementing Ion Mobility Spectrometry as a Cleaning Verification Method," Pharm. Technol.27 (3), 22–25 (2002).

3. D. Brand, X. Li, and T. Wortley, "Ion Trap Mobility Spectrometry: Reducing Downtime in Cleaning Validation and Verification," GE Sensing, www.gesensing.com/toolsupport/whitepaper.htm accessed June 16, 2009.

4. D. Brand et al., "Direct Swabbing and Surface Recovery with Ion Trap Mobility Spectrometry," GE Sensing, www.gesensing.com/products/resources/datasheets/GEsensing_whitepaperfinal.pdf accessed June 2, 2009.

5. R. DeBono, "Ion Mobility Spectrometry: A Fast, Sensitive, and Robust HPLC Alternative," Appl. in Chrom. March, 20–23 (2002), http://trace.smithsdetection.com/Documents/LifeSciences/LE203sBarringer.pdf.

6. G.A. Eiceman, "Advances in Ion Mobility Spectrometry," Crit. Rev. Anal. Chem.22 (1, 2), 471–490 (1990).